• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在新辅助放疗期间排除髂外淋巴结照射可降低下肠道毒性,且不会损害肿瘤累及前部结构的T4b期直肠癌患者的疗效。

Excluding external iliac node irradiation during neoadjuvant radiotherapy decreases lower intestinal toxicity without compromising efficacy in T4b rectal cancer patients with tumours involving the anterior structures.

作者信息

Li Anchuan, Mao Miaobin, Chen Runfan, Chi Pan, Huang Ying, Wu Junxin, Xu Benhua

机构信息

Department of Radiation Oncology, Fujian Medical University Union Hospital, Xinquan Road 29, Fuzhou, 350001, China.

Department of Radiation Oncology, College of Clinical Medicine, Fujian Medical University, Fuzhou, 350001, China.

出版信息

Discov Oncol. 2024 Mar 16;15(1):76. doi: 10.1007/s12672-024-00885-6.

DOI:10.1007/s12672-024-00885-6
PMID:38492016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10944434/
Abstract

PURPOSE

To explore the impact of excluding the external iliac node (EIN) from the clinical target volume (CTV) during preoperative radiotherapy in T4b rectal cancer with anterior structure invasion.

METHODS

We retrospectively identified 132 patients with T4b rectal cancer involving the anterior structures who received radiotherapy followed by surgery between May 2010 and June 2019. Twenty-nine patients received EIN irradiation (EIN group), and 103 did not (NEIN group). Failure patterns, survival and toxicities were compared between the two groups.

RESULTS

The most common failure was distant metastasis (23.5%). 11 (8.3%) patients developed locoregional recurrence, 10 (9.7%) patients were in the NEIN group, and 1 (3.4%) was in the EIN group (P = 0.34). The EIN region failure was rare (1/132, 0.8%). The locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), overall survival (OS) and progression-free survival (PFS) rates were 96.3% vs. 90.5%, 82.1% vs.73.7%, 75.9% vs. 78.0% and 72.4% vs. 68.3% (all P > 0.05) for the EIN group and NEIN group, respectively. The incidence of grade 3-4 acute toxicity in the lower intestine was significantly higher in the EIN group than in the NEIN group (13.8% vs. 1.9%, P = 0.02). The Dmax, V35 and V45 of the small bowel was decreased in the NEIN group compared to the EIN group.

CONCLUSIONS

Exclusion of the EIN from the CTV in T4b rectal cancer with anterior structure invasion could reduce lower intestinal toxicity without compromising oncological outcomes. These results need further evaluation in future studies.

摘要

目的

探讨在术前放疗中,对于侵犯前方结构的T4b期直肠癌患者,将髂外淋巴结(EIN)排除在临床靶区(CTV)之外的影响。

方法

我们回顾性分析了2010年5月至2019年6月期间132例接受放疗后手术的侵犯前方结构的T4b期直肠癌患者。29例患者接受了EIN照射(EIN组),103例未接受(非EIN组)。比较两组的失败模式、生存率和毒性反应。

结果

最常见的失败是远处转移(23.5%)。11例(8.3%)患者发生局部区域复发,非EIN组10例(9.7%),EIN组1例(3.4%)(P = 0.34)。EIN区域失败罕见(1/132,0.8%)。EIN组和非EIN组的局部区域无复发生存率(LRFS)、远处转移无复发生存率(DMFS)、总生存率(OS)和无进展生存率(PFS)分别为96.3%对90.5%、82.1%对73.7%、75.9%对78.0%和72.4%对68.3%(所有P > 0.05)。EIN组下肠道3-4级急性毒性反应的发生率显著高于非EIN组(13.8%对1.9%,P = 0.02)。与EIN组相比,非EIN组小肠的Dmax、V35和V45降低。

结论

对于侵犯前方结构的T4b期直肠癌患者,将EIN排除在CTV之外可降低下肠道毒性,且不影响肿瘤学结局。这些结果需要在未来的研究中进一步评估。

相似文献

1
Excluding external iliac node irradiation during neoadjuvant radiotherapy decreases lower intestinal toxicity without compromising efficacy in T4b rectal cancer patients with tumours involving the anterior structures.在新辅助放疗期间排除髂外淋巴结照射可降低下肠道毒性,且不会损害肿瘤累及前部结构的T4b期直肠癌患者的疗效。
Discov Oncol. 2024 Mar 16;15(1):76. doi: 10.1007/s12672-024-00885-6.
2
Patterns of failure and implications for clinical target volume definition of locally advanced T4b rectal cancer identified with magnetic resonance imaging and treated using neoadjuvant chemoradiotherapy and surgery.采用磁共振成像技术诊断并经新辅助放化疗和手术治疗的局部晚期 T4b 直肠癌失败模式及对临床靶区定义的影响。
Radiother Oncol. 2021 Aug;161:132-139. doi: 10.1016/j.radonc.2021.06.017. Epub 2021 Jun 12.
3
Necessity of external iliac lymph nodes and inguinal nodes radiation in rectal cancer with anal canal involvement.直肠癌侵犯肛管时行髂外淋巴结和腹股沟淋巴结放疗的必要性。
BMC Cancer. 2022 Jun 14;22(1):657. doi: 10.1186/s12885-022-09724-9.
4
[Thirty years' changes of the strategy of lateral lymph node dissection in low rectal cancer: treatment experience and prognostic analysis of 289 cases in one single center].[低位直肠癌侧方淋巴结清扫策略30年变迁:单中心289例治疗经验及预后分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Oct 25;24(10):889-896. doi: 10.3760/cma.j.cn.441530-20200920-00530.
5
[Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].新辅助放化疗联合全盆腔脏器切除术治疗原发性T4b期直肠癌的疗效分析
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jan 25;22(1):59-65.
6
Excluding the ischiorectal fossa irradiation during neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy followed by abdominoperineal resection decreases perineal complications in patients with lower rectal cancer.在新辅助放化疗后行腹会阴联合切除术中,排除调强放疗对坐骨直肠窝的照射可降低低位直肠癌患者的会阴并发症。
Radiat Oncol. 2019 Aug 5;14(1):138. doi: 10.1186/s13014-019-1338-5.
7
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.术前超分割放化疗用于既往盆腔放疗后的局部复发性直肠癌患者:一项多中心II期研究。
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18.
8
Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective.直肠癌侧方盆壁淋巴结复发的映射:放射肿瘤学家的视角。
J Cancer Res Clin Oncol. 2018 Jun;144(6):1119-1128. doi: 10.1007/s00432-018-2624-6. Epub 2018 Mar 15.
9
Is Elective Inguinal or External Iliac Irradiation During Neoadjuvant (Chemo)radiotherapy Necessary for Locally A dvanced Lower Rectal Cancer With Anal Sphincter Invasion?局部进展期低位直肠癌合并肛门括约肌侵犯行新辅助(放)化疗时是否有必要选择性腹股沟或髂外照射?
Pract Radiat Oncol. 2022 Mar-Apr;12(2):125-134. doi: 10.1016/j.prro.2021.10.003. Epub 2021 Oct 17.
10
Distant Metastasis is the Dominant Cause of Treatment Failure after Lateral Lymph Node Dissection in Patients with Lateral Lymph Node Metastasis: Results of the Large Multicenter Lateral Node Study in China.远处转移是侧方淋巴结转移患者行侧方淋巴结清扫术后治疗失败的主要原因:中国大型多中心侧方淋巴结研究结果
J Cancer. 2023 Oct 2;14(17):3227-3237. doi: 10.7150/jca.88009. eCollection 2023.

本文引用的文献

1
Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factors.ACCORD12/0405-PRODIGE02 研究中的局部区域复发:剂量学研究和危险因素。
Radiother Oncol. 2021 Aug;161:198-204. doi: 10.1016/j.radonc.2021.06.006. Epub 2021 Jun 16.
2
Patterns of failure and implications for clinical target volume definition of locally advanced T4b rectal cancer identified with magnetic resonance imaging and treated using neoadjuvant chemoradiotherapy and surgery.采用磁共振成像技术诊断并经新辅助放化疗和手术治疗的局部晚期 T4b 直肠癌失败模式及对临床靶区定义的影响。
Radiother Oncol. 2021 Aug;161:132-139. doi: 10.1016/j.radonc.2021.06.017. Epub 2021 Jun 12.
3
Therapeutic effects and limitations of chemoradiotherapy in advanced lower rectal cancer focusing on T4b.
聚焦 T4b 期的中低位进展期直肠癌的放化疗疗效及局限性
Int J Colorectal Dis. 2021 Jul;36(7):1525-1534. doi: 10.1007/s00384-021-03936-4. Epub 2021 May 3.
4
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.局部晚期直肠癌患者的 FOLFIRINOX 新辅助化疗和术前放化疗(UNICANCER-PRODIGE 23):一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13.
5
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era.全直肠系膜切除时代后 T4 期直肠癌手术后的预后因素和失败模式。
Br J Surg. 2019 Nov;106(12):1685-1696. doi: 10.1002/bjs.11242. Epub 2019 Jul 24.
7
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.ACCORD12/0405-PRODIGE02 试验比较两种新辅助放化疗方案治疗中危直肠癌的 5 年晚期毒性和临床结局。
Ann Oncol. 2017 Oct 1;28(10):2436-2442. doi: 10.1093/annonc/mdx351.
8
International consensus guidelines on Clinical Target Volume delineation in rectal cancer.国际直肠癌临床靶区勾画共识指南。
Radiother Oncol. 2016 Aug;120(2):195-201. doi: 10.1016/j.radonc.2016.07.017. Epub 2016 Aug 12.
9
High Rate of Positive Circumferential Resection Margins Following Rectal Cancer Surgery: A Call to Action.直肠癌手术后环周切缘阳性率高:行动呼吁。
Ann Surg. 2015 Dec;262(6):891-8. doi: 10.1097/SLA.0000000000001391.
10
Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes.局部复发和原发性直肠癌患者的多学科综合管理共识声明:超出全直肠系膜切除平面。
Br J Surg. 2013 Jul;100(8):1009-14. doi: 10.1002/bjs.9192.